Clinical trial
An Investigational Drug Co-Administered With Insulin in Patients With Type 2…
NCT00130806 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00130806 |
|---|---|
| Title | An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065) |
| Official title | A Study to Assess the Efficacy and Tolerability of MK0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | MK0478 (muraglitazar), Comparator: placebo |
| Enrollment | 600 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Aug 16, 2005 |
| Last update posted | Sep 7, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: